- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02117453
Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides (STATVAS)
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75014
- Hôpital Cochin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patient > 18 years. ANCA-associated vasculitis: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss syndrome).
Patients will fulfill the Chapel Hill Consensus Criteria and the American College of Rheumatology criteria, in remission of vasculitis.
Patients in remission of vasculitis after induction therapy (for first flare or relapse), including corticosteroids associated or not with immunosuppressive agents according to Good Clinical Practice for the treatment of vasculitis, between 6 months and 10 years after the beginning of induction therapy.
Patients with informed and signed consent
Exclusion Criteria:
Other systemic vasculitis. Secondary vasculitis (paraneoplastic or infectious). Patient with active vasculitis after induction therapy, requiring salvage therapy.
Inability to sign informed consent. Inability to take the experimental treatment. Hypersensitivity to rosuvastatin or to any of the excipients. Pregnancy. Chronic HCV, HBV and/or HIV infection. Patient receiving other statin or other hypolipemic agent. Patient requiring treatment with statin according to Afssaps recommandations published in 2005 as primary or secondary prevention.
Subclinical atherosclerosis that confers a high cardiovascular risk before patient randomization :
- Carotid stenosis greater than 50% in diameter
- Ectasia of the abdominal aorta
- Intima-media thickening greater than 1.2 mm
- Diffuse atherosclerosis lesions
- Heterogeneous or hypoechoic prominent plaques greater than 2 mm
Participation in another interventional study within 3 months before inclusion. Sick patients will not be excluded if they participate simultaneously in a strictlu observational study or a study with only blood samplings.
Any medical or psycatric disease that could prevent from administrating drugs or from following-up the patient according to the protocol, and/or that would expose the patient to an important number of side effects, according to the principal investigator.
Non affiliation to a social security system or any social protection system.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Group I
Rosuvastatin 20 mg/day
|
Rosuvastatin 20 mg/day
|
PLACEBO_COMPARATOR: Group II
Placebo
|
Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean change from baseline in mean carotid intima-media thickness for 2 predefined sites (distal common carotid arteries)
Time Frame: 24 months
|
Assessed with B-mode ultrasound
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of adverse events
Time Frame: 24 months
|
24 months
|
|
Annualized rate of change in mean carotid intima-media thickness for 2 predefined sites (distal common carotid arteries)
Time Frame: 24 months
|
Assessed with B-mode ultrasound
|
24 months
|
Mean change from baseline in the number of plaques in three peripheral vessels (carotid and femoral arteries and abdominal aorta) at 6, 12 and 24 months
Time Frame: 24 months
|
Assessed with B-mode ultrasound
|
24 months
|
Mean change from baseline in serum biomarkers of subclinical atherosclerosis at 6, 12 and 24 months
Time Frame: 24 months
|
ultra-sensitive CRP, VCAM-1, P-selectin, thrombomodulin
|
24 months
|
Rate of major cardiovascular events (myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes)
Time Frame: 24 months
|
24 months
|
|
Rate of vasculitis relapses defined by BVAS>0
Time Frame: 24 months
|
24 months
|
|
Mean change from baseline in lipid profile (triglycerids, total, HDL and LDL cholesterol) at 6, 12 and 24 months compared to baseline value.
Time Frame: 24 months
|
24 months
|
Collaborators and Investigators
Investigators
- Study Chair: Loic Guillevin, MD, PhD, Assistance Publique - Hôpitaux de Paris
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Atherosclerosis
- Vasculitis
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Rosuvastatin Calcium
Other Study ID Numbers
- P120127
- 2013-002531-15 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ANCA-associated Primary Necrotizing Vasculitides
-
Assistance Publique - Hôpitaux de ParisRoche Pharma AGCompletedComparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab (MAINRITSAN3)ANCA-associated VasculitidesFrance
-
University Hospital, Strasbourg, FranceRecruiting
-
Xiangya Hospital of Central South UniversityThe Third Xiangya Hospital of Central South University; Hunan Provincial People... and other collaboratorsRecruiting
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)TerminatedANCA-Associated VasculitisUnited Kingdom
-
Chinese SLE Treatment And Research GroupThe First Affiliated Hospital of Anhui Medical University; Shanghai Zhongshan... and other collaboratorsRecruitingANCA Associated Vasculitis | Maintenance TherapyChina
-
University Hospital Birmingham NHS Foundation TrustMerck Sharp & Dohme LLCRecruitingANCA Associated VasculitisUnited Kingdom
-
University Hospital, BrestNot yet recruitingOccupational Diseases | ANCA Associated Vasculitis | Environmental ExposureFrance
-
Shanghai Zhongshan HospitalCompletedDrug Use | ANCA Associated Vasculitis | JAK-STAT Pathway DeregulationChina
-
Second Affiliated Hospital, School of Medicine,...RecruitingANCA Associated VasculitisChina
-
University of North Carolina, Chapel HillNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)SuspendedANCA Associated VasculitisUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States